SCHEMBL6318486

SCHEMBL6318486

O=CN(c1ccccc1)c1ccc2[nH]nc(-c3ccccc3)c2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCLK1 O15075 1/20 0.52
PRKD3 O94806 1/20 0.52
MAP4K4 O95819 1/20 0.52
CHEK2 O96017 1/20 0.52
CSF1R P07333 1/20 0.52
FER P16591 1/20 0.52
CDK2 P24941 1/20 0.52
MARK3 P27448 1/20 0.52
FLT4 P35916 1/20 0.52
FLT3 P36888 1/20 0.52
MAPK9 P45984 1/20 0.52
CSNK1D P48730 1/20 0.52
CLK2 P49760 1/20 0.52
CSNK2A1 P68400 1/20 0.52
CSNK1G2 P78368 1/20 0.52
MAP4K2 Q12851 1/20 0.52
STK3 Q13188 1/20 0.52
CAMK2B Q13554 1/20 0.52
CAMK2G Q13555 1/20 0.52
DYRK1A Q13627 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500807 0.92 DCLK1 (0.48) DCLK1PRKD3MAP4K4CHEK2CSF1R
SCHEMBL6320728 0.90 AURKA (0.51) DCLK1PRKD3MAP4K4CHEK2CSF1R
SCHEMBL5375043 0.85 CDK2 (0.46) DCLK1PRKD3MAP4K4CHEK2CSF1R
SCHEMBL5382060 0.81 NTRK1 (0.45) CSNK1DMKNK1LRRK2MAP2K4MAPK1
SCHEMBL5374860 0.80 NTRK1 (0.42) DCLK1PRKD3MAP4K4CHEK2CSF1R
SCHEMBL5372291 0.80 MAP2K4 (0.42) CSNK1DAURKBMKNK1LRRK2MAP2K4
SCHEMBL5373376 0.80 NTRK1 (0.44) CLK2DYRK1AMKNK1TTKIDO1
SCHEMBL5372619 0.76 MAPT (0.52) AURKBHPGDMKNK1MAPTALDH1A1
SCHEMBL7152324 0.76 MAP2K4 (0.56) CHEK2FLT3CSNK1DMKNK2STK17A
SCHEMBL11084807 0.75 TTK (0.59) DCLK1PRKD3MAP4K4CHEK2CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SINGNAL PHARMACEUTICALS, INC. 2005-05-19 US disclosed
WO-2002010137-A9 INDAZOLE DERIVATIVES AS JNK INHIBITORS SIGNAL PHARM INC (US) 2003-02-06 WO disclosed
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto SIGNAL PHARMACEUTICALS, LLC 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107457-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 DCLK1 928/4885PRKD3 79/4885MAP4K4 38/4885
US-20020103229-A1 Indazole derivatives as JNK inhibitors and compositions and methods related thereto MAP3K7, MAP3K1, MAP3K8 DCLK1 1054/4885PRKD3 70/4885MAP4K4 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.